Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am out of money or id buy more.
Does anyone predict a pullback in either stocks tomorrow morning?
I plan on buying tomorrow but im not sure to buy on open or ride it out a few hours.
opinions anyone?
How do I view the long and short chart? What website?
Tempted to sell some and buy more nt*k
Stellar Biotechnologies Immunotherapy Technology Demonstrates Protection Against Clostridium Difficile Infection in Preclinical Study
PORT HUENEME, CA--(Marketwired - Oct 21, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today presentation of positive results from a preclinical study of the Company's KLH-conjugate active immunotherapy vaccine demonstrating protection against Clostridium difficile ("C. diff") infection in mice. The study results are being presented this week at the 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClostPath 8) in Queensland, Australia, October 22-26, 2013.
Clostridium difficile is a bacteria found in the intestines that can cause severe and life-threatening intestinal conditions. C. diff infections are at an all-time high and related hospitalizations have tripled in the last decade.
The oral presentation titled "An Anti-C. difficile PSII Polysaccharide-KLH Conjugate Vaccine is Efficacious in Mice" is the result of preclinical research conducted together by scientists from Stellar and the University of Guelph (Ontario, Canada) ("Guelph"). The work relates to Stellar's newly acquired active immunotherapy technology targeting the treatment and diagnosis of C. diff.
Stellar's active immunotherapy technology for C. diff targets cell-surface antigens expressed across many strains of C. diff bacteria. Stellar's approach combines selected polysaccharides of C. diff with Stellar KLH as carrier and adjuvant. The presentation at ClostPath 8 describes the design of a PSII-KLH immunotherapy vaccine and its evaluation in a murine model of C. diff infection.
In the study, the data demonstrated that vaccination with a PSII-KLH conjugate vaccine was effective in conferring protective immunity against C. diff infection, by improving survival in vaccinated mice compared to unvaccinated controls. The study results suggest that Stellar's PSII-KLH active immunotherapy technology shows promise as an effective approach to treating C. diff. Additional preclinical research is underway.
ClostPath 8 is the preeminent scientific conference in the field of clostridial pathogenesis. The meeting covers the latest discoveries presented by leading international researchers.
About Clostridium difficile
Clostridium difficile is a major and growing cause of mortality and morbidity in hospitalized patients. C. diff is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. It causes severe diarrhea and life-threatening intestinal conditions such as colitis. Incidence of C. diff is at a record high in the U.S. with more than 330,000 cases reported annually. Deaths related to C. diff increased 400% in recent years. The cost of C. diff related treatment in the U.S. and Europe is estimated at more than $7 billion annually.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.
How do i use those nice charts that tell you each sell and everything?
I have read alot and thats why i have 3k into it and another 1k tomorrow.
thats about 30% of my retirement... but i believe!
I have $1000 from my 401k available tomorrow im buying with....
just hoping this is in no way a pump and dump stock..
I couldnt wait till my $1k transfer cleared tomorrow, i sold some (money lost) silver stocks and picked up $500 worth today.
BOOM
im going all in and hopfully i dont loose it all like always.
But i believe Wialan, i believe!!!!
Got another $1000 out of my 401k into my brokerage for tomorrows buy.
GO STELLAR! find a cure!
subscribe to their white papers for news and pr emails?
how do you get on Wialan's Email list
Soul Washer
you can give it to me for being dumb and selling the holding i had for a year at .0035 sold at like .001 and lost money but now it would be worth ALOT!!!
and im kicking myself for it. but i bought in this morning with the little i can (due to only being 23 years old)
ill take some donations over here in Alaska :)
haha have a good one.
07/03/2012 YOU BOUGHT REF/93B/SCTS
ACYD AMERICAN CMNTY DEV GROUP INC DEL COM
Cash Shares: +117,720.000 Price: $0.0035 Amount: -$419.97
Comm: $7.95
Settlement Date: 07/09/2012
HATING MYSELF RIGHT NOW....
are there going to be shares to buy tomorrow?
i have a hold on an oil stock that is worth $360, was going to sell that and buy 10000 shares... nothing compaired to the 117720 i had but idk this just ruined my day.
thanks for the info
Still worth buying in? 10/10/2013 tomorrow? I had held 117720 shares and bought it with only like $500-$1000 last year from a stock teaser i seen.
so that plumited to like $150 for my 117720 shares. I finally got sick of the price of my holding dropping to almost nothing.
i sold 100000 shares, kept 17720 of them.
it went up alittle and i sold all the rest to buy SBOTF.
then i started seeing this stock go up up up..
now im P.O.ed!! my holdings would have been alot at 117720 shares for me..
so is it still worth it to buy in at this new price as of today?
Pretty new to this... only like a year of trading.
Dear Stellar Supporter:
We are pleased to report that a second scientific abstract representing the Company’s KLH active immunotherapy program on Clostridium difficile infection (“C. diff”) has been accepted for presentation at the 7th Vaccine & ISV Congress to be held October 27-29, 2013 in Barcelona, Spain.
The poster will be titled “Immunization with Clostridium difficile PSII polysaccharide antigens adjuvanted with KLH induced broad-based enhancement of adaptive immune responses and protection in mice.”
This will be the second of two presentations this month related to Stellar’s C. diff immunotherapy program:
October 22-26, 2013 – ClostPath 8 Conference, Queensland, Australia – Preclinical Oral Presentation
October 27-29, 2013 – 7th Vaccine & ISV Congress, Barcelona, Spain – Preclinical Poster
These presentations are indicative of the development being generated under Stellar’s newly acquired, exclusive license to active immunotherapy technology for the treatment and diagnosis of Clostridium difficile. Stellar’s scientists are working closely with researchers at the University of Guelph (Ontario, Canada) to advance this program.
About Clostridium difficile
Clostridium difficile is a major and growing cause of mortality and morbidity in hospitalized patients. Incidence of C. diff is at a record high in the U.S. with more than 330,000 cases reported in 2009. C. diff is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. It causes severe diarrhea and life-threatening intestinal conditions such as colitis. The cost of C. diff related treatment in the U.S. and Europe is estimated at more than $7 billion annually.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.
Contacts:
Frank Oakes, Chairman
Phone +1 (805) 488-2800
investorrelations@stellarbiotech.com
Investor Relations:
MZ Group
Mark A. McPartland
Senior Vice President
Phone: +1 (646) 593-7140
markmcp@mzgroup.us
Web: www.mzgroup.us
Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.
why the drop today so fast and hard?? every time i get scared and sell, stocks go up.
if i get scared and wait, stocks plumit.
what the heck should i do? sell or hold for the long run?
PORT HUENEME, CA--(Marketwired - Sep 23, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today, further to its news releases of August 22, 2013 and September 10, 2013, the closing of its private placement raising total gross proceeds of US$12,000,000 (the "Private Placement"). The proceeds of the Private Placement will be used for product research, aquaculture and KLH production development, capital expenditures and working capital.
"We are very gratified by the successful and strong closing of this offering. With a sound balance sheet, validation from industry investment, and continued support from Stellar's major shareholders, we can execute our expansion plans with confidence," said Frank Oakes, Stellar President and CEO. "Our team is eager to capitalize on the broadened recognition for Stellar's immunotherapy research and KLH leadership, and turn each strategic initiative into long-term shareholder value."
In connection with the Private Placement, the Company issued a total of 11,428,570 units (the "Units") for total gross proceeds of US$12,000,000, completed in two closings ($10 Million in gross proceeds announced September 10, 2013 (the "Initial Closing") and an additional $2 Million in gross proceeds announced today (the "Final Closing"). The Private Placement included a brokered portion sold to institutional and accredited investors totaling US$5,000,000 (4,761,903 Units) (the "Brokered Offering") and a non-brokered portion totaling US$7,000,000 (6,666,667 Units) (the "Non-brokered Offering").
The Non-Brokered Offering included a US$5,000,000 investment by Amaran Biotechnology, Inc., a privately-held Taiwan biotech company and biopharmaceuticals contract manufacturer.
Each Unit, sold for US$1.05, comprises one share of Stellar's common stock and one half of a share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder to purchase one additional share of Stellar's common stock at a purchase price of US$1.35 for a period of three years from the issuance date of the Warrants.
Newport Coast Securities, Inc., an SEC registered broker-dealer and FINRA member firm, served as exclusive placement agent on behalf of the Company for the Brokered Offering and received a commission totaling US$346,325 and 333,333 placement agent warrants (the "Agent Warrants"). Each Agent Warrant entitles the holder to purchase one additional share of Stellar's common stock at a purchase price of US$1.05 for a period of three years from the issuance date of the Agent Warrants.
Subject to additional requirements imposed by the US Securities Act requiring longer hold-periods on certain of the securities for resale by US subscribers in the US market and a lock-up agreement with certain holders of the securities, the securities issued in the Initial Closing (2,857,143 Brokered Offering Units, 6,666,667 Non-Brokered Offering Units, and 200,000 Agent Warrants) are subject to a hold period expiring January 10, 2014 and the securities issued in the Final Closing (1,904,760 Brokered Offering Units and 133,333 Agent Warrants) are subject to a hold period expiring January 21, 2014.
The securities sold by Stellar in the private placement were not registered under the United States Securities Act of 1933, as amended (the "US Securities Act"), and were sold in reliance upon exemptions from the registration requirements of the US Securities Act. Therefore, such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the US Securities Act and any applicable state securities laws. This press release does not constitute an offer to sell any securities or a solicitation of an offer to purchase any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH operates as both a vital component in many active immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as an antigen for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and core KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of high-quality KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.
Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
..Contact:.
.
Frank Oakes
President and CEO
Phone +1 (805) 488-2800
InvestorRelations@stellarbiotech.com
Investor Relations:
MZ Group
Mark A. McPartland
Senior Vice President
Phone: +1 (212) 301-7130
markmcp@mzgroup.us
Web: www.mzgroup.us
.
.
.....Stellar Biotechnologies Raises US$10 Million in Initial Closing of Private Placement
PORT HUENEME, CA--(Marketwired - Sep 10, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that, further to its news release of August 22, 2013, it has completed the initial closing of its private placement, which included brokered and non-brokered portions, raising initial gross proceeds of US$10M (the "Initial Closing"). The proceeds of the Initial Closing will be used for product research, aquaculture and KLH production development, capital expenditures and working capital.
The non-brokered portion includes a US$5,000,000 investment by Amaran Biotechnology, Inc., a privately-held Taiwan biotech company and biopharmaceuticals contract manufacturer.
"This financing is significant for Stellar on many fronts. This strengthens our balance sheet at a pivotal time of Stellar's growth while the investment from Amaran Biotechnology, Inc. represents active support from life science industry," said Frank Oakes, Stellar President and CEO. "We are very pleased to receive such solid validation from both industry and new investors."
The Initial Closing included a brokered portion sold to institutional and accredited investors totaling US$3,000,000 (2,857,143 Units) (the "Brokered Offering") and a non-brokered portion totaling US$7,000,000 (6,666,667 Units) (the "Non-brokered Offering").
Each Unit, sold for US$1.05, comprises one share of Stellar's common stock and one half of a share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder to purchase one additional share of Stellar's common stock at a purchase price of US$1.35 for a period of three years from the issuance date of the Warrants. The Company anticipates a final closing on or before September 20, 2013.
In connection with the Initial Closing of the Brokered Offering, the placement agent received a commission of US$206,325 and 200,000 Warrants.
Subject to additional requirements imposed by the US Securities Act requiring longer hold-periods on certain of the securities for resale by US subscribers in the US market and a lock-up agreement with certain holders of the securities, the securities issued in the Initial Closing are subject to a hold period expiring January 10, 2014.
The securities sold by Stellar in the private placement were not registered under the United States Securities Act of 1933, as amended (the "US Securities Act"), and were sold in reliance upon exemptions from the registration requirements of the US Securities Act. Therefore, such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the US Securities Act and any applicable state securities laws. This press release does not constitute an offer to sell any securities or a solicitation of an offer to purchase any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.